SG Americas Securities
CARM

SG Americas Securities’s Carisma Therapeutics CARM Stock Holding History

SG Americas Securities’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,671
Closed -$43K – 3013
2023
Q4 		$43K Buy
14,671
+1,018
+7% +$3.03K ﹤0.01% 2939
2023
Q3 		$58K Buy
+13,653
New +$86.4K ﹤0.01% 2905
2022
Q1 		– Sell
-1,391
Closed -$23K – 3008
2021
Q4 		$23K Sell
1,391
-2,002
-59% -$40.3K ﹤0.01% 3258
2021
Q3 		$54K Buy
+3,393
New +$163K ﹤0.01% 3730

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SG Americas Securities's CARM Position: Q1 2024 in Review

SG Americas Securities sold out of Carisma Therapeutics (CARM) in Q1 2024, closing a stake of 14,671 shares — an estimated $43K sold.

SG Americas Securities first reported a position in CARM in Q3 2021 and held it in 4 quarters. The position peaked at $58K in Q3 2023. 51 funds tracked by Wall St. Rank hold CARM as of Q1 2024.

  • SG Americas Securities reported no remaining Carisma Therapeutics position as of Q1 2024 after selling out during the quarter.
  • SG Americas Securities sold 14,671 Carisma Therapeutics shares in Q1 2024, an estimated $43K.
  • SG Americas Securities first reported a position in Carisma Therapeutics in Q3 2021 and held it in 4 quarters.
  • SG Americas Securities's Carisma Therapeutics position peaked at $58K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2024.

Based on SG Americas Securities's 13F filing for Q1 2024, filed 6 May 2024.